TDF better than entecavir at reducing HCC risk, improving survival in CHB patients
Tenofovir disoproxil fumarate (TDF) appears to provide a lower risk of hepatocellular carcinoma (HCC) development and longer survival in patients with chronic hepatitis B (CHB) than entecavir, particularly among treatment-naïve patients and those with underlying cirrhosis, reveals a study.
TDF better than entecavir at reducing HCC risk, improving survival in CHB patients
13 Sep 2021